Slinky Rat personal page - To The Moon

Slinky Rat

Slinky Rat

No personal profile

1Follow

1Followers

0Topic

0Badge

06-23

Results are shit compared to VERU

Data on Novo Nordisk Experimental Weight-Loss Drug Show Mostly Mild Side Effects

06-18

This is not as impressive as Veru's enobosarm. Enobosarm is the REAL deal,

Scholar Rock's Drug Helps Patients on Zepbound Preserve Muscle in Trial

2022-07-25

$Cyngn Inc(CYN)$Haizzzzz

2022-07-25

$Cyngn Inc(CYN)$Why so cruel.... zzzz

2022-05-13

$Cyngn Inc(CYN)$What does the "resell of common stock by shareholders mean???"

2022-05-11

$Veru Inc.(VERU)$I don't understand why the folks are selling sooo low....

2022-04-28

$Vivakor, Inc.(VIVK)$https://www.marketwatch.com/amp/story/vivakor-shares-nearly-double-after-10-year-contract-worth-up-to-250m-271651079760

2022-04-14

$Veru Inc.(VERU)$Why is trading halted ??

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4111922235660882","uuid":"4111922235660882","gmtCreate":1648819165013,"gmtModify":1650563656006,"name":"Slinky Rat","pinyin":"slinkyratslinkyrat","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":1,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.30","exceedPercentage":"80.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.11","exceedPercentage":"80.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":448974089310248,"gmtCreate":1750639287909,"gmtModify":1750644049022,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"Results are shit compared to VERU","listText":"Results are shit compared to VERU","text":"Results are shit compared to VERU","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/448974089310248","repostId":"2545543275","repostType":2,"repost":{"id":"2545543275","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1750668711,"share":"https://ttm.financial/m/news/2545543275?lang=en_US&edition=fundamental","pubTime":"2025-06-23 16:51","market":"fut","language":"en","title":"Data on Novo Nordisk Experimental Weight-Loss Drug Show Mostly Mild Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2545543275","media":"Reuters","summary":"$Novo Nordisk(NVO)$ on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results,","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive.</p><p>Shares of Novo Nordisk fell 3.3% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/89069625c36c036955f193211795a122\" tg-width=\"838\" tg-height=\"826\"/></p><p>The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo&#39;s shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.</p><p>The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine.</p><p>In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients.</p><p>In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group.</p><p>&#34;Everything was in line with what we expected,&#34; Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters.</p><p>The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group.</p><p>Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. &#34;Those patients on lower doses actually had higher weight loss reduction,&#34; she said. &#34;We&#39;ve not really seen that before because we have not had powerful treatments that have got people close to target.&#34;</p><p>CagriSema is a weekly injection that combines Novo&#39;s blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin.</p><p>The CagriSema Phase 3 trial results &#34;compared very favorably also with what we&#39;ve seen with tirzepatide, which was previously the best-in-class,&#34; Dr. Davies said.</p><p>Eli Lilly&#39;s LLY.N tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks.</p><p>Dr. Davies said it makes sense to have more options for patients, including &#34;theoretical benefits&#34; with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body&#39;s metabolic adaptation to weight loss, she said.</p><p>Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026.</p><p>&#34;We expect to see approval maybe around the beginning of 2027,&#34; Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes.</p><p>Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. &#34;This also allows them to lose their body weight at a pace that isn&#39;t too steep. It also mitigates side effects,&#34; he said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Data on Novo Nordisk Experimental Weight-Loss Drug Show Mostly Mild Side Effects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nData on Novo Nordisk Experimental Weight-Loss Drug Show Mostly Mild Side Effects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-23 16:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive.</p><p>Shares of Novo Nordisk fell 3.3% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/89069625c36c036955f193211795a122\" tg-width=\"838\" tg-height=\"826\"/></p><p>The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo&#39;s shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.</p><p>The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine.</p><p>In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients.</p><p>In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group.</p><p>&#34;Everything was in line with what we expected,&#34; Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters.</p><p>The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group.</p><p>Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. &#34;Those patients on lower doses actually had higher weight loss reduction,&#34; she said. &#34;We&#39;ve not really seen that before because we have not had powerful treatments that have got people close to target.&#34;</p><p>CagriSema is a weekly injection that combines Novo&#39;s blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin.</p><p>The CagriSema Phase 3 trial results &#34;compared very favorably also with what we&#39;ve seen with tirzepatide, which was previously the best-in-class,&#34; Dr. Davies said.</p><p>Eli Lilly&#39;s LLY.N tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks.</p><p>Dr. Davies said it makes sense to have more options for patients, including &#34;theoretical benefits&#34; with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body&#39;s metabolic adaptation to weight loss, she said.</p><p>Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026.</p><p>&#34;We expect to see approval maybe around the beginning of 2027,&#34; Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes.</p><p>Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. &#34;This also allows them to lose their body weight at a pace that isn&#39;t too steep. It also mitigates side effects,&#34; he said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nL1N3SO060:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2545543275","content_text":"Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive.Shares of Novo Nordisk fell 3.3% in premarket trading.The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine.In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients.In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group.\"Everything was in line with what we expected,\" Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters.The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group.Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. \"Those patients on lower doses actually had higher weight loss reduction,\" she said. \"We've not really seen that before because we have not had powerful treatments that have got people close to target.\"CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin.The CagriSema Phase 3 trial results \"compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class,\" Dr. Davies said.Eli Lilly's LLY.N tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks.Dr. Davies said it makes sense to have more options for patients, including \"theoretical benefits\" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said.Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026.\"We expect to see approval maybe around the beginning of 2027,\" Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes.Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. \"This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects,\" he said.","news_type":1,"symbols_score_info":{"NVO":1.1}},"isVote":1,"tweetType":1,"viewCount":305,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":447376064200760,"gmtCreate":1750260547214,"gmtModify":1750260550955,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"This is not as impressive as Veru's enobosarm. Enobosarm is the REAL deal,&nbsp;","listText":"This is not as impressive as Veru's enobosarm. Enobosarm is the REAL deal,&nbsp;","text":"This is not as impressive as Veru's enobosarm. Enobosarm is the REAL deal,","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/447376064200760","repostId":"2544197194","repostType":4,"repost":{"id":"2544197194","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1750247100,"share":"https://ttm.financial/m/news/2544197194?lang=en_US&edition=fundamental","pubTime":"2025-06-18 19:45","market":"us","language":"en","title":"Scholar Rock's Drug Helps Patients on Zepbound Preserve Muscle in Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2544197194","media":"Reuters","summary":"June 18  - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.Shares of Scholar Rock jumped 13.8% in premarket trading.Scholar's drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.E","content":"<html><head></head><body><p>June 18 (Reuters) - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly&#39;s weight-loss treatment Zepbound.</p><p>Shares of Scholar Rock jumped 13.8% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/7f41e7b50f5a1bb8b6d4d83ed874e3d1\" tg-width=\"839\" tg-height=\"620\"/></p><p>Scholar&#39;s drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.</p><p>Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.</p><p>Earlier this month, Regeneron said its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk&#39;s popular obesity drug Wegovy.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scholar Rock's Drug Helps Patients on Zepbound Preserve Muscle in Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScholar Rock's Drug Helps Patients on Zepbound Preserve Muscle in Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-18 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>June 18 (Reuters) - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly&#39;s weight-loss treatment Zepbound.</p><p>Shares of Scholar Rock jumped 13.8% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/7f41e7b50f5a1bb8b6d4d83ed874e3d1\" tg-width=\"839\" tg-height=\"620\"/></p><p>Scholar&#39;s drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.</p><p>Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.</p><p>Earlier this month, Regeneron said its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk&#39;s popular obesity drug Wegovy.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999015978.USD":"利安颠覆性创新基金A","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LLY":"礼来","LU0882574055.USD":"富达全球健康医疗A ACC","LU0238689110.USD":"贝莱德环球动力股票基金","SRRK":"Scholar Rock Holding Corp","BK4599":"减肥药","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","BK4534":"瑞士信贷持仓","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","BK4139":"生物科技","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999001176.USD":"United Global Healthcare Acc USD","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nL4N3SL0QA:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2544197194","content_text":"June 18 (Reuters) - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.Shares of Scholar Rock jumped 13.8% in premarket trading.Scholar's drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.Earlier this month, Regeneron said its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy.","news_type":1,"symbols_score_info":{"SRRK":0.9,"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9900242795,"gmtCreate":1658719498917,"gmtModify":1676536197366,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>Haizzzzz","listText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>Haizzzzz","text":"$Cyngn Inc(CYN)$Haizzzzz","images":[{"img":"https://community-static.tradeup.com/news/b2ac25659147e37728e1f1a2fa0e4a53","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/9900242795","isVote":1,"tweetType":1,"viewCount":1245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9900242146,"gmtCreate":1658719377886,"gmtModify":1676536197350,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>Why so cruel.... zzzz","listText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>Why so cruel.... zzzz","text":"$Cyngn Inc(CYN)$Why so cruel.... zzzz","images":[{"img":"https://community-static.tradeup.com/news/1b55a0eb30204deabc02ce27db2be64f","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":2,"link":"https://ttm.financial/post/9900242146","isVote":1,"tweetType":1,"viewCount":1055,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9067178060,"gmtCreate":1652432682750,"gmtModify":1676535099612,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>What does the \"resell of common stock by shareholders mean???\"","listText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>What does the \"resell of common stock by shareholders mean???\"","text":"$Cyngn Inc(CYN)$What does the \"resell of common stock by shareholders mean???\"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9067178060","isVote":1,"tweetType":1,"viewCount":1393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9064336053,"gmtCreate":1652277131172,"gmtModify":1676535067186,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VERU\">$Veru Inc.(VERU)$</a>I don't understand why the folks are selling sooo low....","listText":"<a href=\"https://ttm.financial/S/VERU\">$Veru Inc.(VERU)$</a>I don't understand why the folks are selling sooo low....","text":"$Veru Inc.(VERU)$I don't understand why the folks are selling sooo low....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9064336053","isVote":1,"tweetType":1,"viewCount":1630,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4112220729965662","authorId":"4112220729965662","name":"OneStream","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"authorIdStr":"4112220729965662","idStr":"4112220729965662"},"content":"two groups- the big pharma pouring out shares they gathered before to suppress veru price (competitor/ potential cheap buyout target); and those short term day traders quick buy sell for a bit gain.","text":"two groups- the big pharma pouring out shares they gathered before to suppress veru price (competitor/ potential cheap buyout target); and those short term day traders quick buy sell for a bit gain.","html":"two groups- the big pharma pouring out shares they gathered before to suppress veru price (competitor/ potential cheap buyout target); and those short term day traders quick buy sell for a bit gain."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9060508943,"gmtCreate":1651159776868,"gmtModify":1676534861533,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VIVK\">$Vivakor, Inc.(VIVK)$</a>https://www.marketwatch.com/amp/story/vivakor-shares-nearly-double-after-10-year-contract-worth-up-to-250m-271651079760","listText":"<a href=\"https://ttm.financial/S/VIVK\">$Vivakor, Inc.(VIVK)$</a>https://www.marketwatch.com/amp/story/vivakor-shares-nearly-double-after-10-year-contract-worth-up-to-250m-271651079760","text":"$Vivakor, Inc.(VIVK)$https://www.marketwatch.com/amp/story/vivakor-shares-nearly-double-after-10-year-contract-worth-up-to-250m-271651079760","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9060508943","isVote":1,"tweetType":1,"viewCount":1157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9089914238,"gmtCreate":1649943993884,"gmtModify":1676534612384,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VERU\">$Veru Inc.(VERU)$</a>Why is trading halted ??","listText":"<a href=\"https://ttm.financial/S/VERU\">$Veru Inc.(VERU)$</a>Why is trading halted ??","text":"$Veru Inc.(VERU)$Why is trading halted ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089914238","isVote":1,"tweetType":1,"viewCount":794,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3564840252730012","authorId":"3564840252730012","name":"SeriouSyrius","avatar":"https://community-static.tradeup.com/news/9ccc1cd6c73ef8677b9a4dd6cdb39e7b","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3564840252730012","idStr":"3564840252730012"},"content":"Its call short circuit, sudden huge drop or rise will trigger it. Suddenly drop very fast just now so halted.","text":"Its call short circuit, sudden huge drop or rise will trigger it. Suddenly drop very fast just now so halted.","html":"Its call short circuit, sudden huge drop or rise will trigger it. Suddenly drop very fast just now so halted."}],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9900242146,"gmtCreate":1658719377886,"gmtModify":1676536197350,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>Why so cruel.... zzzz","listText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>Why so cruel.... zzzz","text":"$Cyngn Inc(CYN)$Why so cruel.... zzzz","images":[{"img":"https://community-static.tradeup.com/news/1b55a0eb30204deabc02ce27db2be64f","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":2,"link":"https://ttm.financial/post/9900242146","isVote":1,"tweetType":1,"viewCount":1055,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9064336053,"gmtCreate":1652277131172,"gmtModify":1676535067186,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VERU\">$Veru Inc.(VERU)$</a>I don't understand why the folks are selling sooo low....","listText":"<a href=\"https://ttm.financial/S/VERU\">$Veru Inc.(VERU)$</a>I don't understand why the folks are selling sooo low....","text":"$Veru Inc.(VERU)$I don't understand why the folks are selling sooo low....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9064336053","isVote":1,"tweetType":1,"viewCount":1630,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4112220729965662","authorId":"4112220729965662","name":"OneStream","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"authorIdStr":"4112220729965662","idStr":"4112220729965662"},"content":"two groups- the big pharma pouring out shares they gathered before to suppress veru price (competitor/ potential cheap buyout target); and those short term day traders quick buy sell for a bit gain.","text":"two groups- the big pharma pouring out shares they gathered before to suppress veru price (competitor/ potential cheap buyout target); and those short term day traders quick buy sell for a bit gain.","html":"two groups- the big pharma pouring out shares they gathered before to suppress veru price (competitor/ potential cheap buyout target); and those short term day traders quick buy sell for a bit gain."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9900242795,"gmtCreate":1658719498917,"gmtModify":1676536197366,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>Haizzzzz","listText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>Haizzzzz","text":"$Cyngn Inc(CYN)$Haizzzzz","images":[{"img":"https://community-static.tradeup.com/news/b2ac25659147e37728e1f1a2fa0e4a53","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/9900242795","isVote":1,"tweetType":1,"viewCount":1245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9089914238,"gmtCreate":1649943993884,"gmtModify":1676534612384,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VERU\">$Veru Inc.(VERU)$</a>Why is trading halted ??","listText":"<a href=\"https://ttm.financial/S/VERU\">$Veru Inc.(VERU)$</a>Why is trading halted ??","text":"$Veru Inc.(VERU)$Why is trading halted ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089914238","isVote":1,"tweetType":1,"viewCount":794,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3564840252730012","authorId":"3564840252730012","name":"SeriouSyrius","avatar":"https://community-static.tradeup.com/news/9ccc1cd6c73ef8677b9a4dd6cdb39e7b","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3564840252730012","idStr":"3564840252730012"},"content":"Its call short circuit, sudden huge drop or rise will trigger it. Suddenly drop very fast just now so halted.","text":"Its call short circuit, sudden huge drop or rise will trigger it. Suddenly drop very fast just now so halted.","html":"Its call short circuit, sudden huge drop or rise will trigger it. Suddenly drop very fast just now so halted."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":447376064200760,"gmtCreate":1750260547214,"gmtModify":1750260550955,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"This is not as impressive as Veru's enobosarm. Enobosarm is the REAL deal,&nbsp;","listText":"This is not as impressive as Veru's enobosarm. Enobosarm is the REAL deal,&nbsp;","text":"This is not as impressive as Veru's enobosarm. Enobosarm is the REAL deal,","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/447376064200760","repostId":"2544197194","repostType":4,"repost":{"id":"2544197194","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1750247100,"share":"https://ttm.financial/m/news/2544197194?lang=en_US&edition=fundamental","pubTime":"2025-06-18 19:45","market":"us","language":"en","title":"Scholar Rock's Drug Helps Patients on Zepbound Preserve Muscle in Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2544197194","media":"Reuters","summary":"June 18  - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.Shares of Scholar Rock jumped 13.8% in premarket trading.Scholar's drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.E","content":"<html><head></head><body><p>June 18 (Reuters) - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly&#39;s weight-loss treatment Zepbound.</p><p>Shares of Scholar Rock jumped 13.8% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/7f41e7b50f5a1bb8b6d4d83ed874e3d1\" tg-width=\"839\" tg-height=\"620\"/></p><p>Scholar&#39;s drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.</p><p>Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.</p><p>Earlier this month, Regeneron said its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk&#39;s popular obesity drug Wegovy.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scholar Rock's Drug Helps Patients on Zepbound Preserve Muscle in Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScholar Rock's Drug Helps Patients on Zepbound Preserve Muscle in Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-18 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>June 18 (Reuters) - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly&#39;s weight-loss treatment Zepbound.</p><p>Shares of Scholar Rock jumped 13.8% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/7f41e7b50f5a1bb8b6d4d83ed874e3d1\" tg-width=\"839\" tg-height=\"620\"/></p><p>Scholar&#39;s drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.</p><p>Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.</p><p>Earlier this month, Regeneron said its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk&#39;s popular obesity drug Wegovy.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999015978.USD":"利安颠覆性创新基金A","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LLY":"礼来","LU0882574055.USD":"富达全球健康医疗A ACC","LU0238689110.USD":"贝莱德环球动力股票基金","SRRK":"Scholar Rock Holding Corp","BK4599":"减肥药","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","BK4534":"瑞士信贷持仓","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","BK4139":"生物科技","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999001176.USD":"United Global Healthcare Acc USD","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nL4N3SL0QA:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2544197194","content_text":"June 18 (Reuters) - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.Shares of Scholar Rock jumped 13.8% in premarket trading.Scholar's drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.Earlier this month, Regeneron said its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy.","news_type":1,"symbols_score_info":{"SRRK":0.9,"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":448974089310248,"gmtCreate":1750639287909,"gmtModify":1750644049022,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"Results are shit compared to VERU","listText":"Results are shit compared to VERU","text":"Results are shit compared to VERU","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/448974089310248","repostId":"2545543275","repostType":2,"repost":{"id":"2545543275","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1750668711,"share":"https://ttm.financial/m/news/2545543275?lang=en_US&edition=fundamental","pubTime":"2025-06-23 16:51","market":"fut","language":"en","title":"Data on Novo Nordisk Experimental Weight-Loss Drug Show Mostly Mild Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2545543275","media":"Reuters","summary":"$Novo Nordisk(NVO)$ on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results,","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive.</p><p>Shares of Novo Nordisk fell 3.3% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/89069625c36c036955f193211795a122\" tg-width=\"838\" tg-height=\"826\"/></p><p>The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo&#39;s shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.</p><p>The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine.</p><p>In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients.</p><p>In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group.</p><p>&#34;Everything was in line with what we expected,&#34; Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters.</p><p>The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group.</p><p>Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. &#34;Those patients on lower doses actually had higher weight loss reduction,&#34; she said. &#34;We&#39;ve not really seen that before because we have not had powerful treatments that have got people close to target.&#34;</p><p>CagriSema is a weekly injection that combines Novo&#39;s blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin.</p><p>The CagriSema Phase 3 trial results &#34;compared very favorably also with what we&#39;ve seen with tirzepatide, which was previously the best-in-class,&#34; Dr. Davies said.</p><p>Eli Lilly&#39;s LLY.N tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks.</p><p>Dr. Davies said it makes sense to have more options for patients, including &#34;theoretical benefits&#34; with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body&#39;s metabolic adaptation to weight loss, she said.</p><p>Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026.</p><p>&#34;We expect to see approval maybe around the beginning of 2027,&#34; Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes.</p><p>Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. &#34;This also allows them to lose their body weight at a pace that isn&#39;t too steep. It also mitigates side effects,&#34; he said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Data on Novo Nordisk Experimental Weight-Loss Drug Show Mostly Mild Side Effects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nData on Novo Nordisk Experimental Weight-Loss Drug Show Mostly Mild Side Effects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-23 16:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive.</p><p>Shares of Novo Nordisk fell 3.3% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/89069625c36c036955f193211795a122\" tg-width=\"838\" tg-height=\"826\"/></p><p>The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo&#39;s shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.</p><p>The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine.</p><p>In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients.</p><p>In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group.</p><p>&#34;Everything was in line with what we expected,&#34; Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters.</p><p>The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group.</p><p>Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. &#34;Those patients on lower doses actually had higher weight loss reduction,&#34; she said. &#34;We&#39;ve not really seen that before because we have not had powerful treatments that have got people close to target.&#34;</p><p>CagriSema is a weekly injection that combines Novo&#39;s blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin.</p><p>The CagriSema Phase 3 trial results &#34;compared very favorably also with what we&#39;ve seen with tirzepatide, which was previously the best-in-class,&#34; Dr. Davies said.</p><p>Eli Lilly&#39;s LLY.N tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks.</p><p>Dr. Davies said it makes sense to have more options for patients, including &#34;theoretical benefits&#34; with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body&#39;s metabolic adaptation to weight loss, she said.</p><p>Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026.</p><p>&#34;We expect to see approval maybe around the beginning of 2027,&#34; Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes.</p><p>Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. &#34;This also allows them to lose their body weight at a pace that isn&#39;t too steep. It also mitigates side effects,&#34; he said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nL1N3SO060:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2545543275","content_text":"Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive.Shares of Novo Nordisk fell 3.3% in premarket trading.The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine.In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients.In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group.\"Everything was in line with what we expected,\" Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters.The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group.Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. \"Those patients on lower doses actually had higher weight loss reduction,\" she said. \"We've not really seen that before because we have not had powerful treatments that have got people close to target.\"CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin.The CagriSema Phase 3 trial results \"compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class,\" Dr. Davies said.Eli Lilly's LLY.N tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks.Dr. Davies said it makes sense to have more options for patients, including \"theoretical benefits\" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said.Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026.\"We expect to see approval maybe around the beginning of 2027,\" Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes.Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. \"This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects,\" he said.","news_type":1,"symbols_score_info":{"NVO":1.1}},"isVote":1,"tweetType":1,"viewCount":305,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9067178060,"gmtCreate":1652432682750,"gmtModify":1676535099612,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>What does the \"resell of common stock by shareholders mean???\"","listText":"<a href=\"https://ttm.financial/S/CYN\">$Cyngn Inc(CYN)$</a>What does the \"resell of common stock by shareholders mean???\"","text":"$Cyngn Inc(CYN)$What does the \"resell of common stock by shareholders mean???\"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9067178060","isVote":1,"tweetType":1,"viewCount":1393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9060508943,"gmtCreate":1651159776868,"gmtModify":1676534861533,"author":{"id":"4111922235660882","authorId":"4111922235660882","name":"Slinky Rat","avatar":"https://community-static.tradeup.com/news/2c467c9bad7aeac91dee2fe928f5cfaf","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4111922235660882","idStr":"4111922235660882"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VIVK\">$Vivakor, Inc.(VIVK)$</a>https://www.marketwatch.com/amp/story/vivakor-shares-nearly-double-after-10-year-contract-worth-up-to-250m-271651079760","listText":"<a href=\"https://ttm.financial/S/VIVK\">$Vivakor, Inc.(VIVK)$</a>https://www.marketwatch.com/amp/story/vivakor-shares-nearly-double-after-10-year-contract-worth-up-to-250m-271651079760","text":"$Vivakor, Inc.(VIVK)$https://www.marketwatch.com/amp/story/vivakor-shares-nearly-double-after-10-year-contract-worth-up-to-250m-271651079760","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9060508943","isVote":1,"tweetType":1,"viewCount":1157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}